Regeneron Pharmaceuticals legal and compliance interviews test whether candidates understand the regulatory, intellectual property, and compliance frameworks that govern a biopharmaceutical company where FDA promotional regulation compliance, patent defense against biosimilar challenges, collaboration agreement legal governance for the Sanofi partnership, and Anti-Kickback Statute compliance for healthcare provider interactions define the core legal work. Legal at Regeneron spans FDA promotional compliance (where Regeneron's commercial activities for DUPIXENT, EYLEA, and LIBTAYO must comply with the requirements governing prescription drug promotion – fair balance between efficacy and risk information in all promotional materials, accurate and non-misleading efficacy claims supported by substantial evidence from adequate and well-controlled studies, prohibition on promotion of unapproved indications or patient populations not covered by the approved labeling, and the Office of Prescription Drug Promotion enforcement process that reviews promotional materials and issues untitled letters or warning letters when violations are found – and where Regeneron's medical-legal-regulatory review process for all promotional materials must be rigorous enough to catch compliance issues before materials reach healthcare providers or patients), patent portfolio management and biosimilar litigation (where EYLEA's composition of matter and method-of-treatment patents are subject to challenge through FDA's Biologics Price Competition and Innovation Act pathway – biosimilar applicants can challenge relevant patents through inter partes review proceedings at the Patent Trial and Appeal Board and through patent infringement litigation in federal court triggered by the 42-day notice of commercial marketing – and where legal must manage the litigation strategy that determines how long EYLEA's market exclusivity is protected, and where DUPIXENT's patent portfolio requires ongoing prosecution, maintenance, and licensing strategy to protect the innovation value that the VelocImmune platform generates), Sanofi collaboration agreement legal governance (where the collaboration agreements governing DUPIXENT, LIBTAYO, and other joint assets require legal interpretation when commercial decisions create disputes about profit-sharing calculations, development expense allocations, or the scope of Sanofi's commercialization rights in particular markets – and where contract governance requires legal to advise the joint committees that manage the collaboration on whether proposed strategic decisions are within the authority the agreements grant), and OIG/Anti-Kickback compliance for HCP interactions (where Regeneron's speaker programs, consulting arrangements, advisory boards, and patient assistance programs must comply with the federal Anti-Kickback Statute's prohibition on remuneration intended to induce healthcare provider referrals – and where the safe harbors available for legitimate commercial arrangements require careful structuring and documentation to ensure that HCP compensation reflects fair market value for services and that patient assistance programs satisfy the OIG's compliance guidance on co-pay assistance). Interviewers evaluate whether candidates understand FDA promotional compliance enforcement, biologic patent BPCIA litigation, collaboration agreement governance, and pharmaceutical Anti-Kickback compliance.
Start your free Regeneron Pharmaceuticals Legal & Compliance practice session.
What interviewers actually evaluate
FDA Promotional Compliance, Biologic Patent Defense, and Sanofi Collaboration Legal Governance
Regeneron legal interviews probe whether candidates understand how pharmaceutical legal practice differs from general corporate legal work in the promotional compliance dimension (FDA's prohibition on off-label promotion means that Regeneron's commercial representatives cannot proactively discuss clinical data for uses not approved in the current label – even if Regeneron has submitted a supplemental BLA for a new indication and has strong clinical evidence supporting it – until the supplement is approved and the new indication is included in the updated label, requiring legal to maintain clear boundaries between promotional activity that can precede approval and the off-label communication that must wait for approval, and to manage the gray areas where HCPs ask about unapproved uses at medical conferences and sales calls), the BPCIA patent litigation complexity (biosimilar applications for EYLEA under the BPCIA trigger a complex patent dance – the exchange of information about the biosimilar's manufacturing process and the reference product holder's patents, followed by a list of patents that Regeneron believes could be infringed, followed by patent infringement lawsuits that must be resolved or stayed before commercial marketing begins, with IPR proceedings at the PTAB running concurrently – requiring pharmaceutical patent litigation expertise that spans composition of matter, formulation, and method patents in the biologics context), and the collaboration governance legal challenge (Regeneron's collaboration agreements with Sanofi are complex long-term commercial contracts that were negotiated years before DUPIXENT or LIBTAYO achieved their current commercial scale – interpreting those agreements in situations that the parties did not specifically anticipate, like the emergence of new competitive threats or the launch of new indications that affect the geographic scope of co-promotion rights, requires contract lawyers who understand both the commercial intent of the collaboration and the literal terms that govern it when commercial interests diverge).
The Inflation Reduction Act's Medicare drug price negotiation provisions create an emerging legal practice area for Regeneron: engaging with CMS in the IRA negotiation process for EYLEA's Part B price requires legal counsel who understands the administrative law framework for negotiation, the constitutional challenges to the IRA's negotiation structure that pharmaceutical companies have pursued in federal court, and how the negotiation process affects Regeneron's ability to maintain the EYLEA pricing strategy that supports its financial projections.
What gets scored in every session
Specific, sentence-level feedback.
| Dimension | What it measures | How to answer |
|---|---|---|
| FDA promotional compliance and OPDP enforcement | Do you understand the FDA's requirements for fair balance, accurate claims, and off-label promotion prohibition – how promotional materials are reviewed for compliance, what OPDP enforcement actions look like, and how to advise the commercial organization on the boundary between permissible promotion and off-label marketing that triggers regulatory risk? We flag legal answers that treat pharmaceutical promotion as standard advertising compliance without engaging with FDA's substantive promotional requirements. | Fair balance analysis, off-label promotion boundaries, OPDP enforcement response protocol |
| BPCIA biologic patent litigation and IPR defense | Can you describe how biosimilar patent litigation under the BPCIA works for EYLEA – what the patent dance exchange involves, how Regeneron identifies the patents to assert, how IPR proceedings at the PTAB run parallel to district court litigation, and what the strategic considerations are in deciding which patents to assert aggressively versus which to reserve? We score whether your patent analysis engages with the BPCIA-specific litigation process rather than standard pharmaceutical Hatch-Waxman analysis. | BPCIA patent dance procedure, IPR defense strategy, district court and PTAB coordination |
| Sanofi collaboration agreement legal governance | Do you understand how to provide legal governance for Regeneron's collaboration agreements with Sanofi – how to interpret the agreements in situations not specifically contemplated at drafting, how to advise the joint committees on the limits of their authority under the collaboration terms, and how to manage a commercial disagreement with Sanofi through the agreement's dispute resolution process? We detect legal answers that treat collaboration governance as contract administration rather than ongoing legal strategy. | Collaboration term interpretation, joint committee authority boundaries, commercial dispute resolution |
| Anti-Kickback compliance for HCP interactions | Can you describe how to ensure that Regeneron's speaker programs, advisory boards, and patient assistance programs comply with the Anti-Kickback Statute – what fair market value documentation is required for HCP compensation, how to design patient assistance programs that satisfy OIG guidance, and what Sunshine Act aggregate spend reporting requires from a compliance program design perspective? We flag legal answers that treat pharmaceutical HCP compliance as equivalent to generic vendor relationship management. | AKS safe harbor compliance for speaker programs, patient assistance OIG guidance, Sunshine Act aggregate spend monitoring |
How a session works
Step 1: Choose a Regeneron Pharmaceuticals legal and compliance scenario – FDA promotional compliance and OPDP enforcement management, EYLEA biosimilar patent litigation and BPCIA patent dance strategy, Sanofi collaboration agreement interpretation and dispute governance, or Anti-Kickback compliance program design for healthcare provider interactions.
Step 2: The AI interviewer asks realistic Regeneron-style questions: how you would advise the DUPIXENT commercial team when a sales representative reports that during a routine dermatology office call, a physician asked proactively about DUPIXENT's efficacy data in a pediatric age group for which FDA approval has been submitted but not yet received – and how the representative should respond in a way that does not constitute impermissible off-label promotion while serving the physician's legitimate clinical inquiry, how you would develop the litigation strategy for defending EYLEA's composition of matter patents in PTAB inter partes review proceedings filed by multiple biosimilar applicants who are challenging the validity of the same patent claims on obviousness grounds, or how you would interpret the Sanofi collaboration agreement's provision governing the allocation of co-promotion expenses when Regeneron proposes to significantly increase its field force for a new DUPIXENT indication that Sanofi's commercialization plan does not reflect.
Step 3: You respond as you would in the actual interview. The system scores your answer on FDA promotional compliance, BPCIA patent litigation, collaboration governance, and Anti-Kickback compliance.
Step 4: You get sentence-level feedback on what demonstrated genuine pharmaceutical legal expertise and what needs stronger BPCIA patent litigation analysis or FDA promotional compliance specificity.
Frequently Asked Questions
How does FDA promotional compliance work at a commercial pharmaceutical company?
FDA's regulations at 21 CFR Part 202 and the agency's guidance documents establish requirements for prescription drug promotion that apply to all communications by or on behalf of the manufacturer intended to induce sales. Fair balance requires that risk information is presented with a prominence and readability reasonably comparable to the efficacy claims – if a DUPIXENT advertisement prominently features patients with clear skin, the risks of injection site reactions, conjunctivitis, and other adverse events must be disclosed with reasonable prominence. Claims must be accurate and not misleading, and must be supported by substantial evidence from adequate and well-controlled clinical investigations. Off-label promotion is prohibited – commercial representatives cannot promote DUPIXENT for indications beyond those listed in the current approved labeling, even if robust clinical data exists for additional uses pending regulatory approval. Regeneron's promotional review process submits materials to FDA's Drug Listing and Labeling Group and maintains documentation of compliance review before any materials are deployed.
How does BPCIA biosimilar litigation work for EYLEA?
The Biologics Price Competition and Innovation Act created a complex patent litigation framework specifically for biologic reference product holders and biosimilar applicants. After FDA accepts a biosimilar application referencing EYLEA, the applicant shares its abbreviated BLA and manufacturing process information with Regeneron, and Regeneron provides a list of potentially infringed patents. The parties then exchange contentions about infringement and validity before Regeneron files patent infringement suits within 30 days. FDA cannot approve the biosimilar for 12 years from EYLEA's original approval, and the pending litigation creates a 30-month stay of biosimilar approval or until the courts rule, whichever comes first. Parallel inter partes review proceedings at the PTAB can invalidate composition of matter or other patents independently of the district court litigation, requiring Regeneron to defend its patent claims simultaneously in two different forums with different legal standards and timelines.
How are Regeneron's collaboration agreements with Sanofi governed legally?
The Regeneron-Sanofi collaboration agreements are complex commercial contracts that govern the joint development and commercialization of DUPIXENT, LIBTAYO, and other shared assets – specifying how development costs are shared, how US and international commercialization responsibilities are allocated, how profits are split, and what decision-making authority the joint committees have over major product decisions. Legal's role includes interpreting these agreements when commercial decisions create questions about contractual authority – whether a proposed marketing spend is within the joint committee's approved budget, whether a new indication falls within the geographic scope of Sanofi's commercialization rights, or whether a manufacturing change requires collaboration committee approval. When interpretive disagreements arise, the agreements specify escalation and dispute resolution processes that legal must manage to resolve commercial disputes without destroying the collaborative relationship that sustains DUPIXENT's global commercial success.
What does Anti-Kickback Statute compliance require for pharmaceutical HCP interactions?
The federal Anti-Kickback Statute prohibits offering, paying, soliciting, or receiving remuneration to induce or reward referrals of items or services covered by federal healthcare programs. For Regeneron's commercial interactions with prescribing physicians, the primary compliance risk areas are speaker programs – where physicians are paid to speak to other physicians about DUPIXENT at promotional programs – and consulting and advisory board arrangements where physicians provide advice in exchange for honoraria. The AKS safe harbors for personal services and management contracts require that compensation be set in advance at fair market value, that the services be specified in a written agreement, and that the services be commercially reasonable independent of the value of any referrals. Regeneron must establish and document that speaker fees and consulting fees reflect the physician's actual expertise and market rate for comparable services, not the physician's prescribing volume or prescribing potential.
How does the Inflation Reduction Act affect Regeneron's legal strategy?
The IRA's Medicare drug price negotiation program requires CMS to negotiate prices for certain high-spend Medicare drugs with no generic or biosimilar competition. EYLEA was selected in the first round of Part B drug negotiations, and DUPIXENT may face negotiation in future rounds. The legal issues raised by IRA negotiation include administrative law challenges – pharmaceutical companies including Merck and others have filed lawsuits challenging the IRA's negotiation process as unconstitutional compelled speech and as an unlawful seizure of intellectual property without just compensation – and practical compliance issues around the negotiation process itself, including how to structure maximum fair price agreements with CMS and how negotiated prices interact with Regeneron's existing commercial contracts. Regeneron's engagement with the IRA negotiation process requires legal counsel who understands administrative law, constitutional challenges to pharmaceutical price regulation, and the commercial implications of negotiated prices for Regeneron's Medicare revenue.
Also practice
One full session free. No account required. Real, specific feedback.
